The Effect of Exenatide on Fasting Bile Acids

NCT04303819 · Completed

Last updated 2026-05-28

This clinical trial tested the effect of the medication exenatide on fasting bile acid levels in people with type 2 diabetes who are also obese.

Status Completed The study has finished.

Type Observational

Participants 38 people

Who can join Ages 18–65 · all sexes

Timeline Started 2020-01 · est. completion 2020-01

Where 1 site · China

What this study is testing ClinicalTrials.gov NCT04303819 ↗

Description as written by the study sponsor.

Newly diagnosed T2DM participants without hypoglycemic drugs intake were retrospective analyzed. Plasma total bile acids in fasting state (FTBAs) and other parameters were compared before and after exenatide treatment and correlation analysis between changes of FTBAs and glycemic parameters.

Treatments tested

Exenatide treatment also known as exenatide Drug

12 weeks of exenatide injection, 5 μg twice a day by subcutaneous injection for 4 weeks, followed by 10 μg twice a day for 8 weeks, as recommended by the drug manufacturer.

Main thing measured	Plasma total bile acids in fasting state
Sponsor	Beijing Chao Yang Hospital
Conditions studied	Type 2 Diabetes Mellitus in Obese
GLP-1 drugs	exenatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT04303819 ↗